Julie Zorn
Senior Director, Antibody Engineering
Julie has over 10 years of industrial experience engineering large molecule therapeutics. Prior to joining BigHat she worked at Genentech, Bristol Myers Squibb, and most recently at Gilead where she was a Director of Protein Therapeutics. She has led computational and experimental approaches to multi-specific design, characterization of therapeutic mechanisms of action for approved therapeutics, and the development of diverse therapeutic assets, most notably including immune cell engagers. She received her Ph.D. in chemical biology from the University of California, San Francisco and completed her postdoctoral research with an emphasis in structural biology at the University of California, Berkeley.
